This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Our series of industry trend research reports — created using our flagship 360-assessment tool, Benchmarks® for Managers — shows that great similarities exist among leaders across industries including healthcare, pharmaceutical, financial, tech, energy, and government (civilian). Army leaders would stack up against industry leaders.
Or a benchmarking exercise might lead a functional leader to argue for new investment in distribution networks (‘Our competitors have them’ or ‘We must be great at this’) without recognizing that your existing distribution network, while it may not be the best, is more than adequate for your way to play, and the investment is better made elsewhere.
In explaining pharmaceutical firm GlaxoSmithKline's decision in 2009 to end this practice, CEO Andrew Witty said that "the company's decision was driven by the long-term nature of the pharmaceutical industry, which meant short-term financial indicators were of limited use.". CEOs should actively court desirable investors.
There’s a similar assumption underlying much of the discussion around how to measure the return on marketing investment, where it seems to be tacitly accepted that attitudinal insights are insufficient at senior decision-making levels, and behavioral insights represent today’s benchmarks. After all, it’s hard work to capture attitudes.
A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades.
There’s a similar assumption underlying much of the discussion around how to measure the return on marketing investment, where it seems to be tacitly accepted that attitudinal insights are insufficient at senior decision-making levels, and behavioral insights represent today’s benchmarks.
One pharmaceutical company's overly-cautious sales force expansion strategy resulted in too little support for a new product launch and cost the company 17% of profits over three years. A sales force stays affordable by keeping costs in line with industry or company benchmarks for a sales force cost-to-sales ratio.
The initiatives included streamlining patient administration in a hospital, implementing a customer-relationship-management (CRM) system in a financial services organization, rolling out a global enterprise-resource-planning (ERP) system for a pharmaceutical company, and promoting collaboration in a technology company.
As a result, some of these Harvard employees earned in excess of $30 million in yearly pay, due to performance that was truly exceptional against industry benchmarks. For years, large pharmaceutical firms purchased small biotech firms with promises to keep their “entrepreneurial rewards” intact.
The paper, co-written with researchers from MIT and Harvard, builds on the work of David Teece, who studied competition in industries like computing and pharmaceuticals. In pharmaceuticals, a drug idea can be patented to protect it from copying. Californias SB 1047 bill even includes a plan for something similar, called CalCompute.
Speed is measurable and can be benchmarked. Distortion of decisions: A number of years ago we studied in detail how the most important decisions like product approvals were made at a large pharmaceutical firm. Think of how fast Netflix is adding new programming and changing the game of television versus traditional networks.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content